---
created: 2025-04-13
updated: 2025-04-13T10:53
id: G0hv%tYJvC
specialty: pharmaco
specialty_id: 437
tags:
  - source/ak-original-decks::step-1::lolnotacop::drugs
  - "source/ak-step1-v11:": 
  - theme/b&b::13-infectious-disease::06-viruses::07-hiv-drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::03-microbiology::07-antimicrobials::53-hiv-therapy
  - "source/ak-step1-v11:": 
  - theme/nbme::21
  - "source/ak-step1-v11:": 
  - theme/nbme::26
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::08-microbiology::28-antivirals
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::02-antivirals::09-fusion-inhibitors
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::07-antimicrobials::06-antivirals-hiv::04-maraviroc,-fusion-inhibitors,-integrase-inhibitors
  - "source/ak-step1-v11:": 
  - theme/uworld::100-999::900-999::953
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::15000-15999::15107
type: flashcard
---

# Question
Maraviroc, an entry inhibitor, inhibits **gp120** of HIV binding to the chemokine receptor **CCR5 (macrophages)**

---

# Answer
Budding of the virus from the cell membrane = final step in the release of newly synthesized HIV virions. Proteases are involved in the final packaging and release of virions, and protease inhibitors prevent successful completion of these steps.    recall that gp120 of HIV binds CD4 and a chemokine receptor (CXCR4 or CCR5) to attach to the host cell